The global hypoparathyroidism treatment market is on the cusp of notable growth, according to a comprehensive analysis ...

Adults with hypoparathyroidism treated with TransCon PTH in the phase 3 PaTHway open-label trial extension demonstrated ...

The global bionic eye market is set to experience substantial growth, advancing at a compound annual growth rate (CAGR) of 12 ...

Septerna's lead and currently only clinical-stage asset is SEP-786, an orally bioavailable parathyroid hormone (PTH) 1 ...

TTR stabilizer in clinical development, lived longer and better as shown in the ATTRibute-CM study. This is the only Phase 3 ...

Total gross proceeds from upsized initial public offering and Series C financing were approximately $251.2 million Last ...

South San Francisco-based Septerna will use most of the IPO proceeds to continue clinical testing of SEP-786 for hypoparathyroidism, an inherited deficiency of parathyroid hormone (PTH).

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of ...

Michele Rayes used to take 64 pills a day to manage her hypoparathyroidism, a rare endocrine disorder that impairs calcium levels, dampens daily quality of life and can sometimes lead ...